Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liposomes | 2 | 2024 | 132 | 0.980 |
Why?
|
| Staphylococcus aureus | 2 | 2024 | 94 | 0.960 |
Why?
|
| Sesquiterpenes | 1 | 2023 | 38 | 0.810 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 67 | 0.760 |
Why?
|
| Anti-HIV Agents | 11 | 2025 | 486 | 0.750 |
Why?
|
| HIV Infections | 15 | 2025 | 2586 | 0.580 |
Why?
|
| Reverse Transcriptase Inhibitors | 6 | 2015 | 57 | 0.460 |
Why?
|
| Ethidium | 2 | 2024 | 9 | 0.420 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2024 | 245 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 2 | 2024 | 432 | 0.320 |
Why?
|
| Triazoles | 3 | 2017 | 102 | 0.310 |
Why?
|
| Bacterial Proteins | 2 | 2024 | 595 | 0.290 |
Why?
|
| HIV-1 | 9 | 2025 | 755 | 0.290 |
Why?
|
| Cyclohexanes | 2 | 2017 | 30 | 0.260 |
Why?
|
| Quinolones | 1 | 2025 | 14 | 0.230 |
Why?
|
| Intensive Care Units | 1 | 2025 | 72 | 0.220 |
Why?
|
| Clinical Competence | 1 | 2025 | 156 | 0.210 |
Why?
|
| Electronic Health Records | 1 | 2025 | 108 | 0.210 |
Why?
|
| Farnesol | 1 | 2023 | 5 | 0.210 |
Why?
|
| HIV Fusion Inhibitors | 2 | 2017 | 5 | 0.200 |
Why?
|
| Drug Therapy, Combination | 9 | 2025 | 234 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2004 | 139 | 0.190 |
Why?
|
| RNA, Viral | 6 | 2025 | 321 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2023 | 1600 | 0.150 |
Why?
|
| Adult | 16 | 2025 | 13872 | 0.150 |
Why?
|
| Lamivudine | 4 | 2012 | 22 | 0.140 |
Why?
|
| Zidovudine | 3 | 2007 | 32 | 0.130 |
Why?
|
| Middle Aged | 13 | 2025 | 12222 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2025 | 201 | 0.130 |
Why?
|
| Stavudine | 3 | 2009 | 13 | 0.130 |
Why?
|
| Disease Transmission, Infectious | 1 | 2017 | 30 | 0.130 |
Why?
|
| Humans | 23 | 2025 | 43102 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 2 | 2022 | 160 | 0.120 |
Why?
|
| Male | 17 | 2025 | 23409 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2025 | 1604 | 0.110 |
Why?
|
| Female | 15 | 2025 | 24698 | 0.100 |
Why?
|
| Adenine | 3 | 2012 | 46 | 0.090 |
Why?
|
| Adolescent | 5 | 2025 | 6081 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2012 | 182 | 0.090 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 191 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 54 | 0.090 |
Why?
|
| Bone Diseases | 1 | 2010 | 18 | 0.080 |
Why?
|
| beta-Lactam Resistance | 1 | 2009 | 4 | 0.080 |
Why?
|
| Acinetobacter | 1 | 2009 | 9 | 0.080 |
Why?
|
| Incidence | 3 | 2025 | 1078 | 0.080 |
Why?
|
| beta-Lactamases | 1 | 2009 | 34 | 0.080 |
Why?
|
| Acinetobacter Infections | 1 | 2009 | 29 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2025 | 2544 | 0.080 |
Why?
|
| Meningoencephalitis | 1 | 2009 | 14 | 0.080 |
Why?
|
| Mycobacterium Infections | 1 | 2009 | 16 | 0.080 |
Why?
|
| Mucormycosis | 1 | 2008 | 2 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2017 | 317 | 0.070 |
Why?
|
| Aged | 6 | 2025 | 8214 | 0.070 |
Why?
|
| Young Adult | 4 | 2025 | 5080 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2008 | 169 | 0.060 |
Why?
|
| Viral Load | 2 | 2025 | 348 | 0.060 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2006 | 7 | 0.060 |
Why?
|
| Dioxolanes | 1 | 2006 | 3 | 0.060 |
Why?
|
| Purine Nucleosides | 1 | 2006 | 14 | 0.060 |
Why?
|
| Acetamides | 1 | 2025 | 11 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2025 | 10 | 0.060 |
Why?
|
| Indazoles | 1 | 2025 | 12 | 0.060 |
Why?
|
| Drug Resistance, Viral | 3 | 2015 | 67 | 0.060 |
Why?
|
| Pyridones | 1 | 2025 | 50 | 0.050 |
Why?
|
| Amides | 1 | 2025 | 71 | 0.050 |
Why?
|
| Dideoxynucleosides | 3 | 2012 | 11 | 0.050 |
Why?
|
| Piperazines | 1 | 2025 | 120 | 0.050 |
Why?
|
| Homosexuality, Male | 2 | 2022 | 486 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 1067 | 0.050 |
Why?
|
| Cyclopropanes | 3 | 2012 | 46 | 0.050 |
Why?
|
| Alkynes | 3 | 2012 | 52 | 0.050 |
Why?
|
| Benzoxazines | 3 | 2012 | 47 | 0.050 |
Why?
|
| Biopsy | 1 | 2004 | 177 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2006 | 307 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 61 | 0.050 |
Why?
|
| Time Factors | 4 | 2011 | 1857 | 0.050 |
Why?
|
| HIV Protease Inhibitors | 1 | 2002 | 24 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 100 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2003 | 226 | 0.040 |
Why?
|
| Deoxycytidine | 2 | 2012 | 38 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2025 | 1546 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 667 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2022 | 182 | 0.040 |
Why?
|
| Neoplasms | 1 | 2011 | 1377 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2023 | 1759 | 0.040 |
Why?
|
| Patient Dropouts | 1 | 2017 | 32 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2022 | 638 | 0.030 |
Why?
|
| Child | 1 | 2025 | 3443 | 0.030 |
Why?
|
| HIV | 1 | 2015 | 100 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2006 | 60 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 1124 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 153 | 0.030 |
Why?
|
| Indinavir | 2 | 2003 | 2 | 0.030 |
Why?
|
| Nelfinavir | 2 | 2003 | 4 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 2853 | 0.020 |
Why?
|
| Ritonavir | 1 | 2012 | 15 | 0.020 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2012 | 31 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 104 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2012 | 109 | 0.020 |
Why?
|
| Pyridines | 1 | 2012 | 139 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2010 | 63 | 0.020 |
Why?
|
| Bone Density | 1 | 2010 | 103 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2009 | 48 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2009 | 15 | 0.020 |
Why?
|
| Granuloma | 1 | 2009 | 24 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 523 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 260 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2009 | 246 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 1154 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 863 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 490 | 0.010 |
Why?
|
| Puerto Rico | 1 | 2009 | 1413 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 280 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 247 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 695 | 0.010 |
Why?
|
| Smoking | 1 | 2011 | 1024 | 0.010 |
Why?
|
| Oxazines | 1 | 2003 | 32 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 465 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 760 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 3994 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 1410 | 0.010 |
Why?
|
| Genotype | 1 | 2003 | 800 | 0.010 |
Why?
|
| Phenotype | 1 | 2003 | 780 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2002 | 233 | 0.010 |
Why?
|